rs199692186
Positions:
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBP6
The NM_001365536.1(SCN9A):āc.3002A>Gā(p.Tyr1001Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000704 in 1,561,280 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.00055 ( 0 hom., cov: 31)
Exomes š: 0.00072 ( 0 hom. )
Consequence
SCN9A
NM_001365536.1 missense
NM_001365536.1 missense
Scores
2
8
9
Clinical Significance
Conservation
PhyloP100: 1.83
Genes affected
SCN9A (HGNC:10597): (sodium voltage-gated channel alpha subunit 9) This gene encodes a voltage-gated sodium channel which plays a significant role in nociception signaling. Mutations in this gene have been associated with primary erythermalgia, channelopathy-associated insensitivity to pain, and paroxysmal extreme pain disorder. [provided by RefSeq, Aug 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -3 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.01835671).
BP6
Variant 2-166272748-T-C is Benign according to our data. Variant chr2-166272748-T-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 130260.We mark this variant Likely_benign, oryginal submissions are: {Uncertain_significance=6, Likely_benign=5, Benign=2}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCN9A | NM_001365536.1 | c.3002A>G | p.Tyr1001Cys | missense_variant | 17/27 | ENST00000642356.2 | NP_001352465.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN9A | ENST00000642356.2 | c.3002A>G | p.Tyr1001Cys | missense_variant | 17/27 | NM_001365536.1 | ENSP00000495601.1 | |||
SCN9A | ENST00000303354.11 | c.3002A>G | p.Tyr1001Cys | missense_variant | 17/27 | 5 | ENSP00000304748.7 | |||
SCN9A | ENST00000409672.5 | c.2969A>G | p.Tyr990Cys | missense_variant | 17/27 | 5 | ENSP00000386306.1 | |||
SCN9A | ENST00000645907.1 | c.2969A>G | p.Tyr990Cys | missense_variant | 17/27 | ENSP00000495983.1 |
Frequencies
GnomAD3 genomes AF: 0.000547 AC: 83AN: 151856Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
83
AN:
151856
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000634 AC: 130AN: 205034Hom.: 0 AF XY: 0.000590 AC XY: 65AN XY: 110138
GnomAD3 exomes
AF:
AC:
130
AN:
205034
Hom.:
AF XY:
AC XY:
65
AN XY:
110138
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000721 AC: 1016AN: 1409424Hom.: 0 Cov.: 31 AF XY: 0.000731 AC XY: 509AN XY: 696032
GnomAD4 exome
AF:
AC:
1016
AN:
1409424
Hom.:
Cov.:
31
AF XY:
AC XY:
509
AN XY:
696032
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000547 AC: 83AN: 151856Hom.: 0 Cov.: 31 AF XY: 0.000553 AC XY: 41AN XY: 74100
GnomAD4 genome
AF:
AC:
83
AN:
151856
Hom.:
Cov.:
31
AF XY:
AC XY:
41
AN XY:
74100
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
2
ALSPAC
AF:
AC:
2
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
9
ExAC
AF:
AC:
70
Asia WGS
AF:
AC:
1
AN:
3478
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:9Benign:7
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:7Benign:1
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Nov 03, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Aug 27, 2013 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2024 | SCN9A: BP4 - |
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The SCN9A p.Tyr990Cys variant was identified in 3 of 3192 proband chromosomes (frequency: 0.00094; one compound heterozygote and two heterozygotes) from individuals with peripheral neuropathy (Wadhawan_2017_PMID_29264398; Eijkenboom_2018_PMID_30554136). The variant was identified in dbSNP (ID: rs199692186) and ClinVar (classified as likely benign by PreventionGenetics, Invitae and Illumina, and as uncertain significance by GeneDx, EGL Genetic Diagnostics and Genetic Services Laboratory, University of Chicago, and classified as pathogenic by Bioinformatics Core Luxembourg Center for Systems Biomedicine). The variant was identified in control databases in 143 of 236408 chromosomes at a frequency of 0.0006049 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: Ashkenazi Jewish in 35 of 6532 chromosomes (freq: 0.005358), Other in 7 of 5826 chromosomes (freq: 0.001202), European (non-Finnish) in 92 of 113582 chromosomes (freq: 0.00081), European (Finnish) in 5 of 22294 chromosomes (freq: 0.000224), African in 3 of 23534 chromosomes (freq: 0.000128) and South Asian in 1 of 20024 chromosomes (freq: 0.00005), but was not observed in the Latino or East Asian populations. The p.Tyr990 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Oct 12, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 13, 2024 | Reported in two individuals with Rolandic epilepsy in published literature; however, no additional information was provided (PMID: 29358611); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29358611, 30554136) - |
Primary erythromelalgia Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Pittsburgh Clinical Genomics Laboratory, University of Pittsburgh Medical Center | Apr 10, 2024 | This sequence variant is a single nucleotide substitution (A>G) at position 3002 of the coding sequence of the SCN9A gene that results in a tyrosine to cysteine amino acid change at residue 1001 of the sodium voltage-gated channel alpha subunit 9 protein. The 1001 residue falls in the cytoplasmic domain between domains II and III (PMID: 20635406). This is a previously reported variant (ClinVar 130260) that has been observed in individuals affected by small fiber neuropathy or Rolandic epilepsy (PMID: 30554136, 37079850, 29358611). In addition, this variant has a been observed in unaffected control cohorts (PMID: 29358611). This variant is present in 213 of 356890 alleles (0.0597%) in the gnomAD population dataset. The frequent observation of this variant in a control population may be the result of incomplete penetrance (PMID: 37079850). Multiple bioinformatic tools provide conflicting predictions concerning the impact of this variant, though this residue is highly conserved across the vertebrate species examined. Studies examining the functional consequence of this variant have not been published, to our knowledge. Based upon the evidence, we consider this a variant of uncertain significance. ACMG Criteria: - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Self-limited epilepsy with centrotemporal spikes Pathogenic:1
Pathogenic, no assertion criteria provided | case-control | Bioinformatics Core, Luxembourg Center for Systems Biomedicine | Jan 01, 2017 | CAADphred>15 - |
Channelopathy-associated congenital insensitivity to pain, autosomal recessive Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 29, 2019 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Generalized epilepsy with febrile seizures plus, type 7;C2752089:Neuropathy, hereditary sensory and autonomic, type 2A Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 27, 2024 | - - |
Small fiber neuropathy Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Paroxysmal extreme pain disorder Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
.;D;.;.;D;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;.;T;T;T;T
M_CAP
Uncertain
D
MetaRNN
Benign
T;T;T;T;T;T
MetaSVM
Uncertain
T
MutationAssessor
Uncertain
.;M;.;.;M;M
PrimateAI
Benign
T
PROVEAN
Pathogenic
D;.;.;.;.;D
REVEL
Uncertain
Sift
Pathogenic
D;.;.;.;.;D
Sift4G
Uncertain
T;T;.;.;.;T
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at